Several of the aforementioned signaling pathways yield an (over-)stimulation of the mammalian target of rapamycin (mTOR), which acts as a master regulator of cellular bioenergetics and which is consequently active in AML (22). Here, MTOR is linked to acute myeloid leukemia.